Navigation Links
AVAX Technologies, Inc. Announces Closing of Bridge Loan Financing
Date:10/30/2008

PHILADELPHIA, Oct. 30 /PRNewswire-FirstCall/ -- AVAX Technologies, Inc. (OTC Bulletin Board: AVXT) (the "Company") today announced that on October 24, 2008, it closed a bridge loan financing pursuant to a Convertible Note and Warrant Purchase Agreement, as amended by the Amendment to Convertible Note and Warrant Purchase Agreement (collectively the "Agreement"). Pursuant to the Agreement, the Company sold convertible promissory notes (the "Notes") in the aggregate principal amount of $1,291,000 and issued warrants (the "Warrants") to purchase an aggregate of 12,910,000 shares of the Company's common stock, par value $0.004 per share, to certain insiders of the Company and accredited investors.

Francois Martelet, Chief Executive Officer of the Company, commented on the closing of the bridge financing, "I am very grateful to our current shareholders for their driving role in completing the bridge against the background of extremely difficult market conditions. The Company's management team and I remain absolutely committed to securing long term financing for the Company as we believe the Company's autologous vaccine platform has tremendous potential in the treatment of cancer."

The Notes and the Warrants were sold without registration under the Securities Act of 1933, as amended (the "Act") and may not be resold unless subsequently registered under the Act or pursuant to an exemption from registration under the Act.

About AVAX Technologies, Inc.

AVAX Technologies, Inc. is a biotechnology company with operations in the United States and Europe. The Company is engaged in the research and clinical and commercial development of biological products and cancer therapeutics. The Company's AC Vaccine platform is a therapeutic cancer vaccine. In addition, the Company performs contract-manufacturing services for biological products for other pharmaceutical and biotechnology companies. More information can be found at http://www.avax-tech.com.

Certain statements in this release are "forward-looking" statements that are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements involve significant risks and uncertainties, and in light of the significant uncertainties inherent in such statements, the inclusion of such information should not be regarded as a representation by the Company that the objectives and plans of the Company will be achieved. In fact, actual results could differ materially from those contemplated by such forward-looking statements. These statements include, but are not limited to, the Company's immediate need to obtain additional funding to continue to finance the Company, the Company's plans, objectives, projections, expectations and intentions such as those relating to the future development of MVax, and the business uncertainties arising from the Company's manufacturing activities at its Lyon, France facility and the logistical issues and risks relating to shipping biologics from the U.S. and other countries to France and the vaccine from France to patients in the U.S. and other countries. Additional information concerning factors that could cause actual results to materially differ from those in the forward looking statements is contained in the Company's public disclosure filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2007 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2008 and June 30, 2008. The Company does not undertake any obligation to release publicly any revisions to these forward- looking statements or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE AVAX Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Advanced Analytical Technologies, Inc. Expands Into New Office and Production Space
2. Arbios Sells HepatAssist Bioartificial Liver System to HepaLife Technologies, Inc.
3. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
4. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
5. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
6. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
7. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
8. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
9. MaxWell Biocorporation, LLC, and International Medical Information Technologies, Inc., Announce Partnership
10. [video] Edward Spink, CEO of TurboSonic Technologies, Inc. Discusses Contract With Biofuel Producer in Exclusive Interview on WallSt.nets 3-Minute Press Show
11. Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing ... MPH, will present information about the company,s programs at the BIOCEO ... New York City . --> ... 5:30PM EST. Registered attendees can request a one on one meeting ... --> New York City . ...
(Date:2/8/2016)... -- --> --> ... ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it ... test to be launched on the Company,s io® platform. By ... test is now cleared for sale within the European Union. ... of the io® CT test signals a new era in ...
(Date:2/5/2016)... , Feb. 5, 2016 ATCC, the ... poised to assist the medical and life science researchers ... Zika Virus infection.   CDC website . ... --> Zika virus is a single-stranded RNA virus ... the West Nile, Dengue and Chikungunya Viruses. Zika virus ...
(Date:2/5/2016)... SAN FRANCISCO , February 5, 2016 ... AMBS), a biotechnology company focused on developing products ... it has requested Rare Pediatric Disease Designation (RPDD) from ... retinitis pigmentosa (RP) with MANF. MANF was previously granted ... December 2014. --> Amarantus BioScience Holdings, Inc. ...
Breaking Biology Technology:
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint ... that Rising Market Are you interested in ... forecasts revenues for checkpoint inhibitors. Visiongain,s report gives ... submarket, product and national level. Avoid falling ... what progress, opportunities and revenues those emerging cancer ...
(Date:2/2/2016)... , Feb. 2, 2016  Based on ... Frost & Sullivan recognizes US-based Intelligent Retinal Imaging ... & Sullivan Award for New Product Innovation. IRIS, ... North America , is poised ... rapidly growing diabetic retinopathy market. The IRIS technology ...
Breaking Biology News(10 mins):